Physician profile
James W Chambliss
NPI 1285856971
$3,107.19
in general payments reported to CMS, 2019-2025
32 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $721 · 2021: $595 · 2022: $491 · 2023: $473 · 2024: $187 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.16 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $308.94 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $277.30 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $236.28 | 2019-2023 | |
| Novo Nordisk INC | $226.80 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $209.61 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $199.79 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $199.10 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $101.41 | 2019-2021 | |
| Amgen INC. | $86.18 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.18 | 2022-2023 | |
| Exact Sciences Corporation | $72.47 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $62.96 | 2019-2024 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.60 | 2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $53.25 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $47.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.20 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.25 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $36.04 | 2021-2022 | |
| Genentech USA, INC. | $31.13 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $28.04 | 2023 | |
| Dexcom, INC. | $27.79 | 2022-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $26.39 | 2019-2023 | Eliquis |
| Allergan, INC. | $24.24 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $18.39 | 2019 | |
| Eisai INC. | $15.61 | 2020 | |
| Axsome Therapeutics, INC. | $14.54 | 2025 | Auvelity |
| Amarin Pharma, INC. | $12.34 | 2020 | |
| Esperion Therapeutics, INC. | $12.24 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.79 | 2021 | |
| Biodelivery Sciences International, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chambliss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.